Details of Drug-Drug Interaction
| Drug General Information (ID: DDIHFJR5CZ) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Sapropterin | Drug Info | Pralatrexate | Drug Info | |||||
| Drug Type | Small molecule | Small molecule | |||||||
| Therapeutic Class | Metabolic Agents | Antimetabolites | |||||||
| Structure | |||||||||
| Mechanism of Sapropterin-Pralatrexate Interaction (Severity Level: Moderate) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Attenuated pharmacological effects (Unspecific) Click to Show/Hide Mechanism Graph | |||||||||
| Drug Name | Sapropterin | Pralatrexate | |||||||
| Mechanism | Tetrahydrobiopterin | Antifolate effects | |||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Pharmacodynamics | ||||||||
| Factor Description | Reduced pharmacological effects leading to insufficient efficacy and/or treatment failure. | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | Caution is advised if sapropterin is used in combination with folate antagonists. The potential for diminished pharmacologic effects of sapropterin should be considered. | ||||||||
| References | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Cerner Multum, Inc. "Australian Product Information.". | ||||||||||||||||||
| 2 | Product Information. Kuvan (sapropterin). BioMarin Pharmaceutical Inc, Novato, CA. | ||||||||||||||||||